Loading organizations...

§ Private Profile · Montreal, Canada
Preclinical biotech company developing gut-restricted small molecule therapeutics using Precision Delivery for IBD, ulcerative colitis.
Based in Montreal, Quebec, Giiant Pharma is a preclinical-stage biotechnology company that develops gut-restricted small molecule therapeutics for gastroenterology conditions. The enterprise utilizes a proprietary Precision Delivery technology platform to create orally administered, microbiota-activated prodrugs, such as its colon-specific PDE4 inhibitor GT-2108, aimed at treating moderate-to-severe ulcerative colitis and other inflammatory bowel diseases. To support its preclinical development programs, the company has secured $11 million in seed financing backed by investors including Genesys Capital, alongside a $500,000 grant from the US Crohn’s and Colitis Foundation. Operating under an out-licensing business model, the firm recently granted worldwide rights for its delivery platform and lead asset to Palisade Bio for further clinical development and commercialization. Established in an undisclosed year by former Merck Frosst scientists, the company is led by co-founders Christophe Mellon, Maxime Ranger, and Elizabeth Kwong.
Giiant Pharma has raised $12.5M across 2 funding rounds.
Giiant Pharma has raised $12.5M in total across 2 funding rounds.
Giiant Pharma has raised $12.5M in total across 2 funding rounds.
Giiant Pharma's investors include Crohn's & Colitis Foundation, Jean-François Pariseau, Jamie Stiff, Mott Family Capital, OrbiMed, AmorChem, Anges Québec, Theodorus.
Giiant Pharma is a Montreal-based preclinical-stage biotech company developing gut-restricted, small-molecule therapeutics for inflammatory bowel diseases (IBD), such as ulcerative colitis.[1][2][3][5] Founded by former Merck Frosst scientists, it builds the Precision Delivery platform, which uses gut microbiota to bioactivate orally administered prodrugs like GT-2108—a colon-specific PDE4 inhibitor—delivering high local concentrations with minimal systemic exposure to improve tolerability and safety.[4][5] The company serves IBD patients suffering from moderate-to-severe symptoms, addressing limitations of existing treatments by enabling precise, tissue-specific action in the lower GI tract.[3][4][5] In 2023, Giiant raised $11 million in seed funding from investors including Amplitude Ventures, Genesys Capital, and AmorChem, fueling its IND-enabling preclinical program and pipeline expansion.[4]
Giiant Pharma was founded in 2010 by two former Merck Frosst scientists—repeat entrepreneurs with deep biotech expertise—who originated the Precision Delivery technology from their prior research.[1][2][3] Dr. Elizabeth Kwong serves as co-founder and chief development officer, while Dr. Maxime Ranger is CEO and chairman, guiding the company's focus on gut-restricted anti-inflammatories.[2][4] Early traction came from academic and venture support, including AmorChem as a founding investor, which spun out the technology from research programs.[3] A pivotal moment was the 2023 $11 million seed round, enabling preclinical advancement of lead candidate GT-2108 for ulcerative colitis.[4]
Giiant rides the wave of precision gastroenterology, where microbiome-targeted drug delivery addresses unmet needs in IBD amid rising prevalence driven by diet, genetics, and aging populations.[4][5] Timing aligns with advances in prodrug tech and microbiota research, amplified by post-pandemic focus on oral therapies over injectables for chronic GI conditions.[3][5] Market forces favor it: IBD affects millions globally with limited safe options, and gut-restricted delivery reduces toxicity risks, positioning Giiant to influence safer standards in a sector projected for growth via VC interest in localized biologics alternatives.[4] By partnering with funds like AmorChem and CQDM, it accelerates Quebec's biotech hub, fostering spinouts from academia into the global pharma pipeline.[3]
Giiant is primed to advance GT-2108 into clinical trials post-IND, potentially expanding its platform to broader GI diseases like Crohn's via microbiota bioactivation innovations.[4][5] Trends in AI-driven drug design and personalized microbiome therapies will shape its path, enhancing precision and scalability. Its influence may grow as a GI delivery pioneer, attracting big pharma partnerships and solidifying Montreal's role in biotech—echoing its origins in Merck-honed science to transform IBD care from systemic risks to targeted relief.[3][5]
Giiant Pharma has raised $12.5M across 2 funding rounds. Most recently, it raised $500K Other Equity in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 10, 2023 | $500K Venture Round | Crohn's & Colitis Foundation | — | Announced |
| May 1, 2021 | $12M Seed | Jean François Pariseau, Jamie Stiff | Mott Family Capital, OrbiMed, AmorChem, Anges Québec, Theodorus | Announced |